HCM News and Press, HUTCHMED (China) Limited From 11/13/22

— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant — ...

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 16 and Thursday, November 17, featuring live webcast presentations from international companies with Am...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab as second-lin...

Hutchmed (China) ( NASDAQ: HCM ) said it began dosing in a phase 2/3 trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China. Warm autoimmune hemolytic anemia is an autoimmune disorder characterized by premature destruction of hea...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmu...

The following slide deck was published by HUTCHMED (China) Limited in conjunction with this event. For further details see: HUTCHMED (China) (HCM) Presents at ESMO Congress 2022

— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32 HR) — — Results to be presented i...

— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the prese...

Despite headwinds from inflation and geopolitical events, CK Hutchison showed good resilience with improvement results in the first half of this year. The dividend also got a bump of 5% for the interim period. With a solid balance sheet and a low valuation it looks tempting but th...

Hutchmed (China) ( NASDAQ: HCM ) and Inmagene Biopharmaceuticals said the first person based in the U.S. was dosed in a global phase 1 trial of IMG-004. Inmagene is developing IMG-004 to potentially treat immunological diseases. The study aims to eva...